Genetics and molecular biology: A cholesterol-lowering drug with antibacterial properties

Current Opinion in Lipidology

Volumn 19, Issue 3, 2008, Pages 324-325

  Linder, Matts D ^a   Ikonen, Elina ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BPH 652; DEHYDROSQUALENE SYNTHASE; HYPOCHOLESTEROLEMIC AGENT; SQUALENE SYNTHASE; SQUALENE SYNTHASE INHIBITOR;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL VIRULENCE; CHOLESTEROL SYNTHESIS; DRUG EFFICACY; HUMAN; MOLECULAR BIOLOGY; MULTIDRUG RESISTANCE; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN STRUCTURE; SEQUENCE HOMOLOGY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTICHOLESTEREMIC AGENTS; BACTERIAL PROTEINS; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; HUMANS; STAPHYLOCOCCUS AUREUS;

EID: 43249128651     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3282ff8630     Document Type: Note

References (11)

1. Liu CI, Liu GY, Song Y, et al. A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. Science 2008; 14 Feb [Epub ahead of print]. This groundbreaking article describes a novel approach to combat Staphylococcus aureus infections, through a surprising link to cholesterol biosynthesis. Blocking the synthesis of the bacterial virulence factor staphyloxanthin by a cholesterol biosynthesis inhibitor increases the susceptibility of S. aureus to the innate immune system. Although S. aureus does not synthesize cholesterol, the enzymatic steps responsible for staphyloxanthin production are remarkably similar to the early steps of cholesterol biosynthesis. Hence, inhibitors of human SQS, proposed as cholesterol-lowering drugs, also block the synthesis of the S. aureus virulence factor. Since SQS inhibitors have already undergone trials in humans, this new strategy might see rapid implementation in the clinics.
2. de Lencastre H, Oliveira D, Tomasz A. Antibiotic resistant Staphylococcus aureus: a paradigm of adaptive power. Curr Opin Microbiol 2007; 10:428-435.
3. Liu GY, Essex A, Buchanan JT, et al. Staphylococcus aureus golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity. J Exp Med 2005; 202:209-215.
4. Ikonen E. Cellular cholesterol trafficking and compartmentalization. Nat Rev Mol Cell Biol 2008; 9:125-138.
5. Magnin DR, Biller SA, Chen Y, et al. alpha-Phosphonosulfonic acids: potent and selective inhibitors of squalene synthase. J Med Chem 1996; 39:657-660.
6. Nishimoto T, Amano Y, Tozawa R, et al. Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro. Br J Pharmacol 2003; 139:911-918.
7. Ishihara T, Kakuta H, Moritani H, et al. Syntheses and biological evaluation of novel quinuclidine derivatives as squalene synthase inhibitors. Bioorg Med Chem 2003; 11:2403-2414.
8. Hiyoshi H, Yanagimachi M, Ito M, et al. Effect of ER-27856, a novel squalene synthase inhibitor, on plasmacholesterol in rhesusmonkeys: comparison with 3-hydroxy-3-methylglutaryl-coa reductase inhibitors. J Lipid Res 2000; 41:1136-1144.
9. Pandit J, Danley DE, Schulte GK, et al. Crystal structure of human squalene synthase. A key enzyme in cholesterol biosynthesis. J Biol Chem 2000; 275:30610-30617.
10. Sharma A, Slugg PH, Hammett JL, Jusko WJ. Clinical pharmacokinetics and pharmacodynamics of a new squalene synthase inhibitor, BMS-188494, in healthy volunteers. J Clin Pharmacol 1998; 38:1116-1121.
11. Sharma A, Slugg PH, Hammett JL, Jusko WJ. Estimation of oral bioavailability of a long half-life drug in healthy subjects. Pharm Res 1998; 15:1782-1786.